NEW YORK (GenomeWeb) – Transgenomic today announced that it has signed an agreement to sell roughly $3 million in restricted stock and warrants through a private placement.

According to the company, the placement includes 1.5 million shares of restricted common stock, as well as fully paid prefunded warrants to purchase up to approximately 700,000 shares of its common stock, in each case at a purchase price of $1.42 per share.

During early morning trading on the Nasdaq, shares of Transgenomic were trading down 7 percent at $1.55.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.